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Diabetes is the most common metabolic disorder and is recognized as one of the most important health threats of our time. MicroRNAs
(miRNAs) are a novel group of non-coding small RNAs that have been implicated in a variety of physiological processes, including glucose
homeostasis. Recent research has suggested that miRNAs play a critical role in the pathogenesis of diabetes and its related cardiovascular
complications. This review focuses on the aberrant expression of miRNAs in diabetes and examines their role in the pathogenesis of endo-
thelial dysfunction, cardiovascular disease, and diabetic retinopathy. Furthermore, we discuss the potential role of miRNAs as blood biomar-
kers and examine the potential of therapeutic interventions targeting miRNAs in diabetes.
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1. Introduction
Diabetes mellitus (DM) is a complex, multisystem disease that repre-
sents the most common metabolic disorder,
1,2 affecting around 8% of
the US population.
3 Type 1 diabetes mellitus (T1DM) results from
insulin deﬁciency,
4 usually secondary to autoimmune b-cell destruc-
tion; and type 2 diabetes mellitus (T2DM) is characterized by
insulin resistance, with or without abnormal insulin secretion.
5 Al-
though T2DM is far more prevalent, both types can result in compli-
cations. Many of the complications of diabetes are vascular in origin,
be they macrovascular and/or microvascular (nephropathy, retinop-
athy, and microangiopathy in several organs), and this puts diabetics
at an increased risk of ischaemic heart disease, renal failure, stroke,
lower limb amputations, and blindness.
6
MicroRNAs (miRNAs) are a family of small ( 22 nucleotide), non-
coding single-strand RNA molecules that were ﬁrst discovered in the
nematode Caenorhabditis elegans in 1993.
7,8 Transcription of miRNAs
occurs through RNA polymerase II
9 and subsequent processing is
mediated by the nuclear ribonuclease III (RNase III) enzyme Drosha
to form precursor miRNAs (70–100 nucleotides). Following trans-
portation to the cytoplasm by exportin 5, a further cleavage occurs
via another RNase III enzyme, Dicer, to form the mature miRNA.
10
miRNAs modulate both physiological and pathological pathways by
post-transcriptionally inhibiting the expression of a plethora of
target genes.
11 Much work has been done on the role of miRNAs
in human disease, especially in cancers and infections.
12,13
The aim of this review is to describe the role of miRNAs in diabetes
and its cardiovascular complications, with reference to the recent re-
search. Speciﬁcally, we look at changes in miRNA expression in dia-
betes, as well as their role in endothelial dysfunction, angiogenesis,
cardiac disease, and retinopathy. We do not discuss diabetic nephro-
pathy, as the role of miRNAs in this complication is well-described in
another review.
14 We also discuss the potential role of miRNAs as
biomarkers in diabetes and how aberrant pathways could be cor-
rected therapeutically. A literature search was performed using
PubMed and Embase to look for relevant papers. The last search
was performed in September 2011. The key search words used
were diabetes, glycaemia, microRNA, and miRNA. References of eli-
gible papers were screened for further relevant studies.
2. MicroRNAs, insulin secretion,
and b-cell function
The pancreatic b-cell and its endocrine product insulin play a central
role in glucose homeostasis and the pathogenesis of diabetes. A
large number of miRNAs have been implicated in normal pancreatic
development and function. Moreover, given the complex interplay
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miR-375, one of the most abundant miRNAs present in islet cells, is
extensively studied in this context. miR-375 negatively regulates
glucose-stimulated insulin secretion (GSIS).
15 In fact, inhibition of
miR-375 enhances insulin secretion, while miR-375 overexpression
impairs the insulin secretory pathway by reducing expression of myo-
trophin (Mtpn), a protein involved in insulin–granule fusion.
15,16 The
effects of miR-375 on Mtpn expression may involve the transcription
factor nuclear factor-kappaB (NF-kB), the activation of which is asso-
ciated with improved GSIS.
17 Indeed, myotrophin functions as a tran-
scription activator of NF-kB in cardiomyocytes, suggesting that the
regulation of myotrophin by miR-375 may lead to changes in NF-kB ac-
tivity.
18miR-375alsotargetsinsulingeneexpression,downregulatingex-
pression of phosphoinositide-dependent protein kinase-1, a key
component in the phosphatidylinositol 3-kinase (PI 3-kinase) signalling
cascade, thus resulting in decreased insulin-induced phosphorylation
of AKT and GSK3 (glycogen synthase kinase 3).
19 High levels of
miR-375arefoundinthepancreaticisletofob/obmice(whichrepresent
amodelofobesity,insulinresistance,andT2DM),
20andinpatientswith
T2DM.
21 Surprisingly, miR-375 knockout mice are hyperglycaemic and
glucose intolerant; changes that occurred secondary to a decrease in
b-cell mass. They also show increased numbers of a-cells and an
elevated plasma glucagons.
20
Several other miRNAs have been shown to have inhibitory roles in
insulin secretion. miR-9 targets the transcription factor Onecut 2,
which inhibits the expression of Granuphilin—a negative regulator
of insulin exocytosis.
22 Overexpression of miR-9 therefore decreases
GSIS. miR-96 also downregulates insulin secretion by decreasing the
expression of nucleolar complex protein 2 (Noc2), a Rab GTPase ef-
fector required for insulin exocytosis, as well as by upregulation of
granuphilin, although this appears to occur via a distinct mechanism
not involving Onecut-2.
23 miR-124a, which is thought to be vital for
pancreatic b-cell development,
24 also modulates several components
of the exocytotic system by directly targeting forkhead box protein
A2 (Foxa2)—a transcription factor involved in glucose metabolism
and insulin secretion.
25 Modulation of miR-124a in MIN6 (mouse insu-
linoma) cells causes changes in Foxa2 and its downstream target gene
PDX-1 (which regulates insulin transcription). miR-124a overexpres-
sion also correlates with downregulation of Kir-6.2 and Sur-1 (sulfo-
nylurea receptor 1), both signiﬁcant regulators of pancreatic
development and function. Overexpression of mir-124a in MIN6
cells leads to increased insulin secretion in response to basal
glucose concentrations and reduced secretion in response to stimula-
tory glucose concentrations.
23
The destruction of pancreatic b-cells is the primary cause of T1DM.
In the early stages, pancreatic islets are inﬁltrated by immune cells,
hence b-cells are exposed to proinﬂammatory cytokines, resulting
in altered insulin content, insulin secretion, and sensitisation to apop-
tosis.
26 High levels of miR-34a were seen in islets from T2DM db/db
mice.
27 Moreover, MIN6 cells treated with proinﬂammatory cytokines
show signiﬁcant induction of miR-21, miR-34a, and miR-146.
28 Subse-
quent blockade of these miRs prevented cytokine-induced reduction
in GSIS and protected b-cells from cytokine-induced cell death. Ex-
perimental chronic exposure to the free fatty-acid palmitate mimics
the adverse environmental conditions that promote failure of
b-cells, arising in defective GSIS. A further study found that exposure
of insulin-secreting cell lines or pancreatic islets to palmitate led to an
increase in miR-34a and miR-146 expression.
27 Overexpression of
miR-34a in MIN6 cells resulted in a decreased GSIS, along with a re-
duction in the expression of the antiapoptotic protein Bcl2 and of
VAMP2 (vesicle-associated membrane protein 2), which is involved
in b-cell exocytosis.
27 While antagonism of either miR-34a or
miR-146 activity partially prevented palmitate-induced b-cell apop-
tosis, normal secretory activity was not restored,
27 suggesting that
palmitate may affect other components of the exocytotic machinery
that are not targeted by the two studied miRNAs.
Diabetes results in prolonged periods of hyperglycaemia. Prolonged
exposure of MIN6 cells to high glucose (HG) results in differential
expression of large numbers of miRNAs, including upregulation of
miR-30d.
29 Overexpression of miR-30d increases insulin gene expres-
sion, whereas its inhibition attenuates glucose-stimulated insulin gene
transcription.
29 In contrast, miR-30d does not modulate insulin secre-
tion.
29 miR-15a promotes insulin biosynthesis by inhibiting endogen-
ous UCP-2 (uncoupling protein-2) expression in mouse b-cells.
30
UCP-2 is a member of the mitochondrial inner membrane family,
and has previously been shown to inhibit GSIS.
31 miR-15a levels
have been shown to increase in parallel with insulin in mouse islets
after short-term exposure to HG concentrations.
30 However, pro-
longed exposure to hyperglycaemia resulted in a downregulation of
both miR-15a and insulin. Transfection of MIN6 cells with miR-15a
increases insulin secretion, and inhibition of miR-15a decreases
insulin levels.
30 Esguerra et al.
32 studied the differential expression
of miRNAs in the pancreatic islets of Wistar and Goto-Kakizaki
(GK) rats—a non-obese model of T2DM that displays hypergly-
caemia, impaired glucose tolerance (IGT), insulin resistance, and
defects in insulin secretion. miR-335 was upregulated in the pancreatic
islets of GK rats, and was shown to target the messenger RNA
(mRNA) for the exocytotic protein Stxbp1.
32 However, many of
the differentially expressed miRNAs had predicted target genes that
are known to be involved in insulin exocytosis.
Figure 1 summarizes the known targets of miRNAs in b-cell
function.
3. MicroRNAs in insulin target
tissues: energy metabolism and
insulin resistance
miRNAs also control insulin signalling in target tissues, including the
liver, skeletal muscle, and adipose tissues. Insulin resistance describes
the failure of target tissues to respond adequately to circulating
insulin. Insulin resistance in adipose tissue and skeletal muscle
reduces glucose uptake and the local storage of triglycerides and
glycogen. Insulin resistance in liver cells leads to reduced glycogen syn-
thesis and storage and concomitant failure to suppress glucose pro-
duction. The end results are elevated blood glucose and free fatty
acid levels, along with raised insulin levels—hallmarks of the metabolic
syndrome. If there is no sufﬁcient compensatory increase in pancreat-
ic b-cell function to counteract the insulin resistance, then T2DM
results.
33
3.1 Adipose tissue
Early studies in Drosophila melanogaster implicated miRNAs in energy
metabolism. Xu et al.
34 found that miR-14 regulates adipocyte droplet
size and triglyceride levels, with miR-14-null ﬂies showing increased
lipid droplet accumulation in adipose tissue that reverted on
re-introduction of the miRNA. Another miRNA of Drosophila
S. Shantikumar et al. 584energy homeostasis, miR-278, may control insulin sensitivity in
adipose tissue: miR-278-knockout ﬂies are lean and display hypergly-
caemia despite having an elevated insulin production, indicating a
loss of insulin sensitivity.
35 This idea is supported by the inappropri-
ately high levels of insulin target genes found in the mutants.
miR-278 acts by regulating the target gene expanded, and overexpres-
sion of this gene resulted in the same features. Although miR-14 and
miR-278 have only been found in insects, a loss of insulin signalling in
mammalian adipose tissue may result in a similar insulin-resistant
phenotype. For example, mice that have had the insulin receptor
gene deleted from adipose tissue are lean.
36
He et al.
37 examined the miRNA expression proﬁles of skeletal
muscle from healthy Wistar and GK rats.
37 The miR-29 family was sig-
niﬁcantly upregulated in the context of diabetes. Further in vitro study
on 3T3-L1 adipocytes suggested that miR-29a and miR-29b were
upregulated by HG and insulin levels. Moreover, miR-29a/b/c overex-
pression reduced insulin-induced glucose import by 3T3-L1 adipo-
cytes, signifying a role in insulin resistance, and this was paralleled
by a decrease in Akt activation, suggesting that the miR-29 family
acts by silencing components of the insulin signalling pathway.
37
However, while in vitro inhibition of the miR-29 family improved Akt
activation, it had little effect on glucose uptake. This may be due in
part to a relatively low endogenous expression of miR-29, but
could also be explained by miR-29 acting on other targets within
the insulin signalling pathway, as yet undetermined, rather than
having a direct effect on Akt.
37 Two genes were also validated as
direct targets of the miR-29 family: Insig1 (insulin-induced gene 1)—an
endoplasmic reticulum membrane protein involved in the control of
cholesterol biosynthesis; and Cav2 (caveolin 2), which is involved
with lipid metabolism, cellular growth, and apoptosis.
37
Insulin stimulates lipogenesis in adipose tissue, transforming blood
glucose into fatty acids for storage of energy. Obesity triggers macro-
phage inﬁltration and cytokine release in adipose tissue, and many of
these cytokines, such as TNFa, interfere with insulin signalling and
inhibit adipogenesis.
38 Some miRNAs that are induced during adipo-
genesis are downregulated in obesity.
39 For example, miR-103 and
miR-143 are upregulated during in vitro and in vivo adipogenesis, and
inhibition of miR-143 inhibits adipocyte differentiation.
39,40 Both
miR-103 and miR-143 are downregulated in the adipocytes from ob/
ob mice.
39 miR-143 antagonism in adipocytes results in
upregulation of the miR-143 target mitogen-activated protein kinase
ERK5/MAPK7,
40 which is known to promote cell proliferation and
differentiation, although the role of ERK5/MAPK7 in adipocytes has
not been investigated. miR-107 has also been shown to accelerate
Figure 1 Schematic overview of the role of microRNAs in b-cell function.
miRNA in diabetes-related cardiovascular diseases 585adipogenesis and is predicted to target pathways that regulate lipid
levels.
41 Levels of miR-143, miR-103, and miR-107 are reduced in adi-
pocytes after treatment with TNFa, suggesting that cytokines contrib-
ute to reduced adipogenesis in obesity.
39 These data indicate that
obesity leads to a loss of miRNA function that is required for adipo-
genesis, and suggest a mechanism for obesity-induced insulin resist-
ance. Other miRNAs that may be involved in insulin resistance
include miR-320 and miR-27b. miR-320 expression in insulin-resistant
adipocytes is 50-fold that of normal 3T3-L1 adipocytes. Ling et al.
42
found that treatment of insulin-resistant adipocytes with
anti-miR-320 increases the insulin sensitivity by targeting p85, which
contributes to cell growth by increasing Akt phosphorylation and
GLUT4 levels. miR-27b is downregulated during adipogenesis from
human multipotent adipose-derived stem cells.
43 Moreover, overex-
pression of miR-27b impairs human adipocyte differentiation and inhi-
bits the peroxisome proliferator-activated receptor (PPARg), the
receptor target for thiazolidinediones—insulin-sensitising agents
used for treating T2DM.
43,44 More recently, miR-130 overexpression
was also found to impair adipogenesis and to repress PPARg.
45 These
connections between miRNA expression and adipogenesis may be
exploited as therapeutic targets in the management of insulin
resistance.
3.2 Liver
Once secreted from the islet, insulin travels via the portal circulation
to the liver, to control hepatic glucose and lipid metabolism, and liver
insulin resistance contributes to the development of the metabolic
syndrome. miR-122 is the most abundant miRNA in the liver.
46 Inhib-
ition of miR-122 in mice results in decreased hepatic fatty acid and
cholesterol synthesis, along with a reduction in plasma cholesterol.
47
In addition, hepatic inhibition of miR-122 in diet-induced obese mice
led to decreased plasma cholesterol, as well as a signiﬁcant improve-
ment in hepatic steatosis. While the authors noted an increase in
phosphorylated AMP-activated protein kinase (AMPK) in the livers
of these mice, they were unable to clarify whether miR-122 directly
regulated AMPK signalling. In any case, targeting miR-122 therapeutic-
ally may correct the imbalances seen in liver insulin resistance.
miR-33a and miR-33b have been shown to regulate cholesterol
homeostasis through interaction with sterol regulatory element-
binding proteins.
48 Davalos et al.
49 have recently reported the role
of these two miRNAs in regulating fatty acid metabolism and insulin
signalling. miR-33a/b inhibit the expression of insulin receptor
substrate-2 (IRS-2) in hepatic cells, subsequently reducing the activa-
tion of downstream insulin signalling pathways, including AKT and
ERK. Antagonism of endogenous miR-33-a/b upregulates fatty acid
oxidation and the response to insulin in hepatocytes, suggesting its
therapeutic potential in the metabolic syndrome.
49
The insulin receptor substrate-1 (IRS-1), like IRS-2, is a signiﬁcant
mediator of insulin signalling. Indeed, IRS-1 knockout mice are insulin-
resistant.
50 Mitochondrial dysfunction is associated with the develop-
ment of insulin resistance as well as with downregulation of IRS-1 in
myocytes.
51 Ryu et al.
52 found that miR-126 was upregulated in the
context of mitochondrial dysfunction in SK-Hep-1 (hepatic cancer)
cells, and reduced expression of IRS-1. miR-145 has been shown to
downregulate IRS-1 protein expression in human colon cancer cells,
resulting in adverse growth and proliferation,
53 although this
miRNA needs further study in the context of diabetes.
A summary of the miRNAs involved in insulin resistance is given in
Figure 2.
3.3 Skeletal muscle
Huang et al.
54 found that miR-24 was signiﬁcantly downregulated in
the skeletal muscle of GK rats. p38 mitogen activated protein kinase
(MAPK) is activated by hyperglycaemia,
55 is overexpressed in GK
rats,
56 and is involved in early diabetic nephropathy in T2DM.
57
Huang et al.
54 conﬁrmed that p38 MAPK is a direct target of
miR-24 in rat tissue.
A list of miRNAs differentially expressed in diabetic models can be
found in Table 1.
4. Endothelial function
and angiogenesis
Vascular complications associated with hyperglycaemia in diabetes
often begin with endothelial dysfunction.
58 Altered expression of mul-
tiple factors results in capillary and arteriole rarefaction in limbs and
heart modiﬁcations
59 and a reduced post-ischaemic angiogenic and
collateral vessel formation.
60–62 Conversely, a pro-angiogenic patho-
genic phenotype is found in the retina.
63 Wang et al.
64 were the ﬁrst
to describe that miRNAs are differently expressed in endothelial cells
(ECs) in the presence of HG. They studied myocardial microvascular
ECs (MMVEC) and compared miRNA expression in GK and Wistar
rats. Of those differentially expressed, miR-320 may target several
angiogenic factors and their receptors, including vascular endothelial
growth factor (VEGF)-A, ﬁbroblast growth factors (FGFs), insulin-like
growth factor 1 (IGF-1), and the IGF-1 receptor.
65,66 Moreover, ele-
vated miR-320 level in diabetic MMVECs was accompanied by
decreased cell proliferation and migration. Subsequent transfection
of an miRNA-320 inhibitor in MMVECs of GK rats improved both
proliferation and migration of these cells and increased the expression
of IGF-1, which is known to promote angiogenesis.
67 The correlation
between elevated miR-320 and suppressed IGF-1 may play a role in
the impaired angiogenesis in diabetes.
Li et al.
68 studied the role of miR-221 in diabetes-induced endothe-
lial dysfunction. miR-221, which is present in human umbilical vein ECs
(HUVECs), participates in angiogenesis regulation by altering the ex-
pression of c-kit (CD117), the receptor for stem cell factor which
additionally promotes endothelial progenitor cell (EPC) migration
and homing.
69 Incubating HUVECs in HG increased miR-221 expres-
sion and reduced c-kit expression, while a miR-221 inhibitor reversed
this inhibitory effect of HG on c-kit expression.
68 Another study by
Togliatto et al.
70 examined the role of miR-221 and miR-222 in HG
and advanced glycation end-product (AGE)-mediated vascular
damage, both in HUVECs and in a model of angiogenesis (Matrigel
plugs) in diabetic mice. They found that HG and high AGEs inhibited
cell cycle progression and resulted in impaired EC and EPC prolifer-
ation as well as reduced angiogenesis. These conditions were also
associated with downregulation of both miR-221 and miR-222 ex-
pression. Additionally, miR-221 and miR-222 were found to directly
inhibit P27KIP1 and P57KIP2 (cyclin-dependent kinase inhibitor pro-
teins that inhibit the cell cycle). Hence, these miRNAs are likely to
be directly involved in AGE/HG-related cell cycle changes.
70 The
results regarding the regulation of miR-221 by glucose levels in
HUVECs are contradictory. While there were some differences in
the cell culture methods, the results in Togliatto et al.
70 were con-
ﬁrmed in vivo. Clearly, further research is needed regarding the role
of miR-221 in the context of HG. Villeneuve et al.
71 examined the
role of miR-125b in vascular smooth muscle cells (VSMCs) cultured
S. Shantikumar et al. 586from T2DM db/db mice. They found that HG upregulated miR-125b,
with parallel downregulation of its predicted target Suv39h1, a
histone-lysine N-methyltransferase. The reduced recruitment of
Suv39h1 at inﬂammatory gene promoters is a key mechanism under-
lying the enhanced inﬂammatory gene expression in db/db micro-
vascular VSMCs (MVSMCs).
72 miR-125b mimics inhibited Suv39h1
protein levels and miR-125b inhibitors had the opposite effect. Fur-
thermore, miR-125b-mediated Suv39h1 knockdown resulted in the
increased expression of inﬂammatory proteins (interleukin 6 and
monocyte chemotactic protein 1) and increased monocyte-MVSMC
binding in hyperglycaemia, thus exhibiting a role for miR-125b in ac-
celerating atherosclerosis.
71
miR-503 is upregulated in myocardial ECs from GK rats,
64 in
3T3-L1 insulin-resistant adipocytes,
42 and in the muscles of T2DM
and insulin-resistant patients.
73 We further examined the role of
miR-503 in angiogenesis in diabetes.
74 miR-503 was upregulated in
HUVECs and human microvascular ECs (HMVECs) cultured in HG/
low growth factor conditions (that mimic ischaemia-induced tissue
starvation in the context of diabetes). HUVECs infected with a lenti-
viral vector expressing premiR-503 showed impaired proliferation, mi-
gration, and cell networking capacities. Under similar conditions,
miR-503 reduced expression of the cell cycle regulators cdc25A
and cyclin E1 (CCNE1). Furthermore, miR-503 inhibition in HG/low
growth factor conditions restored normal EC proliferation and angio-
genesis.
74 We went on to examine the role of miR-503 in diabetic
limb ischaemia to ﬁnd that diabetes increased miR-503 expression
in the ischaemic muscles and ECs extracted from them in comparison
to non-diabetic/non-ischaemic controls. Moreover, in diabetic mice
with induced limb ischaemia, local miR-503 inhibition by injection of
an adenoviral vector containing a decoy sequence for miR-503
improved capillary and arteriolar density, promoted blood ﬂow recov-
ery, and normalized the expression of cdc25 and CCNE1. Important-
ly, miR-503 expression is also increased in the limb muscles and
plasma of diabetic patients undergoing amputation for critical limb is-
chaemia compared with calf biopsies of non-diabetic/non-ischaemic
controls.
74 Our study demonstrates that miR-503 may be a suppres-
sor of post-ischaemic neovascularization in diabetes and thus a poten-
tial therapeutic target. The roles of miRNAs in endothelial dysfunction
and angiogenesis in diabetes are summarized in Figure 3A.
Atherosclerosis is a major vascular complication of diabetes.
Although there is little research on miRNAs in atherosclerosis in
the context of diabetes, the role of miRNAs in the pathogenesis of
atherosclerosis in general has been the subject of two recent
reviews.
75,76
Figure 2 MicroRNAs involved in insulin resistance.
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miR-133 is believed to be expressed speciﬁcally in cardiac and skeletal
muscle, with its function in skeletal muscle being to modulate myo-
blast proliferation and differentiation.
77 Moreover, miR-133 controls
cardiac hypertrophy and is downregulated in failing and hypertrophic
hearts.
78 The GLUT4 glucose transporter is the major mechanism by
which glucose uptake into cardiomyocytes can be increased.
79 Horie
et al.
80 found that miR-133 overexpression lowered GLUT4 levels and
reduced insulin-induced glucose uptake in cardiomyocytes. Addition-
ally, increased miR-133 also reduces the Kru ¨ppel-like transcription
factor KLF15, which induces GLUT4 expression. Furthermore, trans-
fection of cardiac myocytes with a miR-133 decoy increased expres-
sion of both KLF15 and GLUT4, suggesting a direct role in cardiac
glucose transport.
Feng et al.
81 looked at the role of miR-133a in cardiomyocytes in
the context of streptozotocin (STZ)-induced T1DM in mice. Haemo-
dynamic studies conﬁrmed that the T1DM model resulted in cardiac
hypertrophy and poor contractility, and the diabetic hearts displayed
increased expression of MEF2A and MEF2C, two transcription factors
associated with myocardial hypertrophy. Cardiac tissue from the dia-
betic mice displayed signiﬁcant downregulation in miR-133a expres-
sion. In addition, culturing rat neonatal cardiomyocytes in HG also
resulted in downregulation of miR-133a expression.
81 In contrast,
transfection of rat neonatal cardiomyocytes with miR-133a mimics
prevented HG-induced cardiomyocyte hypertrophy, and miR-133a
was shown to mediate its effects by preventing HG-induced upregula-
tion of IGF-1 receptors and SGK1.
82
A prolonged QT interval, an adverse cardiac feature of diabetes,
can result in arrhythmias and has been suggested as an independent
predictor of mortality in DM.
83 Zhang et al.
84 conﬁrmed a 20% pro-
longation of the QT interval in diabetic rabbits compared with con-
trols. This occurs as a result of dysfunction of multiple ion currents/
channels, predominantly the IK/HERG (human ether-a-go-go)
channel. The same group found that levels of miR-133 and miR-1
were signiﬁcantly upregulated in the hearts of diabetic rabbits com-
pared with controls.
85 Furthermore, miR-133 overexpression
reduced HERG protein levels, while miR-133 inhibition partially
reversed this. This suggests a role for miR133 dysfunction in prolong-
ing the QT interval, and causing the resultant arrhythmias, in diabetic
hearts.
85 The above two studies suggest that miR-133 has two poten-
tial roles in the diabetic heart, depending upon whether expression is
increased or decreased. While the signiﬁcance of the differing ﬁndings
has not been determined, there may be species- and/or age-speciﬁc
differences determining the cardiac expression and function of
miR-133 under hyperglycaemia.
Hyperglycaemia-induced apoptosis of cardiomyocytes is related to
diabetic complications,
86 although the mechanisms for this are not
well-deﬁned. IGF-1 is an anti-apoptosis factor which is mediated
through mitochrondria and the cytochrome-c pathway.
87 Yu
et al.
88 studied the effects of IGF-1 and miRNAs in HG-induced
mitochondrial dysfunction. They found that IGF-1 exerted a protect-
ive effect towards apoptosis in rat cardiomyocytes by decreasing the
cytotoxic effects of glucose. miR-1 is overexpressed in the hearts of
diabetic patients.
85 HG increased miR-1 expression, and miR-1 over-
expression inhibits the antiapoptotic action of IGF-1.
88 Heat shock
.......................................................................................................................................................................................
Table 1 List of microRNAs differentially expressed in diabetic models, by tissue, and their potential targets
Tissue Reference Model miRNA changes Up/down-regulated in
diabetes?
Potential targets
Skeletal muscle He et al.
37 GK rat miR29 family (a/b/c) Up Akt
Huang et al.
54 GK rat miR24 Down p38 MAPK
Herrera et al.
119 GK rat miR10b Down
Gallagher et al.
73 Humans miR133 Down
Caporali et al.
74 Humans and diabetic
mice
miR503 Up CDC25a,CCNE1
Liver Herrera et al.
119 GK rat miR195, miR103 Up
Herrera et al.
119 GK rat miR125a Up MAPK pathway
Adipose Tissue Herrera et al.
120 GK rat miR222, miR 27a Up
Herrera et al.
120 GK rat miR125a Up MAPK pathway
Omentum Kloting et al.
121 Humans miR181a Up
miR17-5p, miR132miR 134 Down
Subcutaneous fat Kloting et al.
121 Humans miR147, miR197 Up
miR27a, miR30e, miR140,
miR155, miR210
Down
Endothelial Cells Wang et al.
64 MMVECs miR320 Up VEGF, FGF, IGF-1,
IGF-1-R
Li et al.
68 HUVECS miR221 Up ckit, p27kip1, p57kip2
Villeneuve et al.
71 VSMC miR125b Up suv39h1
Caporali et al.
74 HUVECS/HMVECS miR503 Up CDC, CCNE1
Cardiomyocytes Feng et al.
81 STZ mouse miR133a Down IGF-1-R and SGK1
Zhang et al.
84 Diabetic rabbit miR133, miR1 Up HERG (133 only)
Yu et al.
88 Rat miR1 Up IGF-1
Katare et al.
91 STZ mouse miR1 Up Pim-1
Shan et al.
89 Rat miR1, miR206 Up Hsp60
Retina McArthur et al.
95 STZ rat miR200b Down VEGF
Kovacs et al.
96 STZ rat miR146, miR155, miR132, miR21 Up NF-kB
S. Shantikumar et al. 588protein (Hsp) 60 prevents apoptotic cardiomyocyte death, but has
been shown to be underexpressed in the diabetic heart.
89
Shan et al.
89 examined miR-1 and miR-206 expression in the
hyperglycaemic rat myocardium as well as in rat neonatal cardiomyo-
cytes exposed to HG. They found that HG induced upregulation of
miR-1 and miR-206, and that both miRNAs negatively regulated
Hsp60 expression. Pim-1 (proviral integration site for Moloney
murine leukaemia virus-1) plays a key role in the cardiac response
to stressors.
90 We found that in STZ-T1DM mice, Pim-1 levels
decline during progression of diabetic cardiomyopathy, and
this was associated with a rise in miR-1 expression.
91 Furthermore,
both forced Pim-1 expression and miR-1 inhibition rescued
Pim-1 levels in cardiomyocytes under HG conditions, and this
resulted in a restoration of prosurvival signalling and reduction in
cardiomyocyte apoptosis, suggesting a direct role of miR-1 in inhibit-
ing Pim-1.
91
Another study looking into cardiomyocyte glucose metabolism
found that miR-223 was upregulated in the left ventricle of T2DM
patients. Moreover, miR-223 overexpression induces GLUT4
protein levels in cardiomyocytes,
92 and in vivo miR-223 inhibition sig-
niﬁcantly decreased GLUT4 expression. Given that GLUT4 is down-
regulated in the diabetic heart, it is possible that increasing miR-223
Figure 3 (A) MicroRNAs involved in endothelial dysfunction and angiogenesis in the hyperglycaemic environment. Note the conﬂicting effects of
HG on miR-221 from two separate studies (green arrows
68 and red arrows
70). (B) microRNAs in cardiovascular disease in diabetes.
miRNA in diabetes-related cardiovascular diseases 589levels is an adaptive response aimed to restore normal glucose uptake
in the insulin-resistant heart.
The miRNAs involved in cardiovascular disease in diabetes are
summarized in Figure 3B.
6. Retinopathy
Diabetic retinopathy (DR), one of the leading causes of blindness in
developed countries,
93 is a microvascular complication of diabetes
with multiple underlying pathogenic mechanisms. The altered expres-
sion of growth factors in sustained hyperglycaemia results in both
structural and functional changes in the retina.
63 Elevated VEGF-A
levels, increasing both vessel permeability and neovascularization,
have long been associated with diabetic retinopathy.
94 Only two pub-
lished studies have speciﬁcally looked at the role of miRNAs in DR.
McArthur et al.
95 investigated whether miRNA alterations are
involved in DR in a STZ-T1DM rat model, which is known to result
in early changes of DR. miR-200b, which targets VEGF-A, was
found downregulated in the retinas of diabetic rats. Moreover, in
vitro exposure of HUVECs and bovine retinal capillary ECs (BRECs)
to HG resulted in a downregulation of miR-200b and an upregulation
in VEGF-A mRNA.
95 Subsequent transfection of a miR-200b inhibitor
in HUVECs cultured under normal conditions resulted in a gluco-
mimetic effect of upregulating VEGF-A.
95 VEGF-A-mediated vascular
permeability and tube formation in HUVECs exposed to HG were
reduced upon miR-200b mimic transfection.
95 Additional experimen-
tation was performed in animal models: miR-200b mimic injection into
the vitreous humour of one eye of diabetic mice resulted in local
decreased VEGF-A expression and vascular. Conversely, intravitreal
injection of miR-200b antagomir increased VEGF-A expression, thus
suggesting a role for miR-200b in the pathogenesis of diabetic retinop-
athy and raising support for intravitreal injections as a possible thera-
peutic route for this condition.
95
Kovacs et al.
96 performed miRNA expression proﬁling in the retina
and retinal ECs of STZ-T1DM rats. NF-kB is a regulator of the
immune response and is known to play an important role in the
early pathogenesis of DR by triggering a pro-apoptotic program in
retinal pericytes.
97 miRNAs which are thought to be transcriptionally
regulated by NF-kB (miR-146, miR-155, and miR- 21)
98–100 were also
demonstrated to be upregulated in the retinal ECs of diabetic rats.
96
The authors conﬁrmed that NF-kB was able to directly activate
miR-146 expression. Furthermore, miR-146 overexpression inhibited
interleukin-1b-induced NF-kB activation in retinal ECs, representing a
regulatory negative feedback loop to control NF-kB and miR-146
expression.
96 Thus, overexpression of miR-146 could be exploited
therapeutically through inhibition of NF-kB activation in DR.
7. Biomarkers
There are currently no reliable plasma biomarkers for vascular disease
and endothelial dysfunction. Furthermore, current imaging methods
can visualize the latter stages of macrovascular disease, e.g. athero-
sclerotic plaque, but not endothelial dysfunction, particularly at the
level of microcirculation. Levels of miRNAs in the serum of humans
have been shown to be stable, reproducible, and consistent
amongst healthy individuals, allowing them to be of potential value
as biomarkers of disease.
101 The stability of circulating miRNAs may
be explained by their being carried in membrane-bound vesicles,
102
complexed with Argonaute2,
103,104 or transported by high-density
lipoproteins.
104 The potential role of miRNAs as biomarkers in
wider cardiovascular disease is the subject of another review in this
issue. The discovery of potential-speciﬁc biomarkers may help
predict or detect the development and progression of diabetes and/
or diabetes complications at an early stage, and therefore allow
timely intervention to delay severe complications.
Zampetaki et al.
105 aimed to understand if there is a plasma miRNA
signature for T2DM using a prospective population-based cohort.
They studied 80 patients with T2DM and a further 80 age- and
gender-matched controls.
105 In T2DM, miR-28-3p was
overexpressed, and a further 12 miRNAs were underexpressed.
These ﬁndings were conﬁrmed in T2DM ob/ob mice. A decrease in
circulating miR-126 in non-diabetic people was found to be a signiﬁ-
cant predictor of DM. In fact, the authors detected a gradual
decline in plasma levels of miR-126 from normal glucose tolerance,
through IGT, to diabetes. Some additional miRNAs were predictive
of the future development of diabetes: miR-15a, miR-29b, miR-126,
and miR-223 were lower in those subjects who went on the
develop DM.
105 Using expression proﬁles of the ﬁve most signiﬁcantly
different miRNAs (miR-15a, miR-126, miR-320, miR-223, and
miR-28-3p), controls and diabetics were correctly identiﬁed in 92
and 70% of cases, respectively.
105 Of note, the diabetic patients
who were not detected by the proﬁling method had lower fasting
glucose levels or had well-controlled diabetes. This research suggests
that the use of a miRNAs signature as a biomarker may be a useful
predictive tool in diabetes, although this theory will require conﬁrm-
ation in larger prospective populations and in groups with T1DM.
miR-126 is known to be highly expressed in ECs and to regulate
angiogenesis.
106,107 It facilitates VEGF-A signalling by inhibiting two
of the negative regulators of the VEGF pathway, the Sprouty-related
protein SPRED1 and phosphoinositol-3 kinase regulatory subunit 2
(PIK3R2).
106 miR-126 is also the most abundant miRNA in endothelial
apoptotic bodies, which are thought to be a novel form of communi-
cation between cells.
108 Zampetaki et al. showed that HG conditions
reduced the miR-126 content in endothelial apoptotic bodies pro-
duced by HUVECs in vitro. The authors speculate that, as a conse-
quence of the aforementioned, low delivery of miR-126 to
monocytes in diabetes may result in the previously described
reduced VEGF-A and subsequent endothelial dysfunction, resulting
in defective collateral vessel development.
109 Furthermore, decreasing
miR-126 levels in plasma were associated with a low ankle brachial
pressure index and subsequent new-onset peripheral vascular disease.
Another study explored seven diabetes-related serum miRNAs
(miR-9, miR-29a, miR-34a, miR-30d, miR-124a, miR-146a, and
miR-375) in patients with diabetes, IGT, and in people susceptible
to T2DM with a normal oral glucose tolerance test.
110 While all
seven of the tested miRNAs were signiﬁcantly upregulated in T2DM
cases, there was no difference in the expressed levels between IGT
cases and normal susceptible controls.
110 However, the use of con-
trols that were susceptible to T2DM, rather than those without this
susceptibility, may have had a bearing on this result.
8. Therapeutic applications
The deregulation of miRNA function has been linked to diabetes, al-
though it is not yet fully certain whether this is a cause or effect of the
pathology. If miRNAs are indeed active in the pathogenesis of diabetes
and its related complications, the restoration of normal function by
modifying the expression of speciﬁc miRNAs may be a therapeutic
S. Shantikumar et al. 590target for managing this disease. Chemically modiﬁed siRNA-like oli-
gonucleotides have been used to decrease miRNA expression (antag-
omirs) in vivo.
111,112 However, due to the hypothetical transient nature
of their effects, it is likely that frequent doses may be required to
sustain beneﬁt. Given the chronic nature of diabetes, this would
require the need for repeated injections with their associated costs.
However, a recent study treating chimpanzees with locked nucleic
acid-modiﬁed oligonucleotides complimentary to miR-122 found
that serum cholesterol remained low for over 10 weeks after cessa-
tion of treatment, suggesting that longer-lasting effects may be pos-
sible.
113 Adeno-associated virus (AAV) vectors containing miRNA
mimics have been found to promote miRNA expression in vivo.
114
For example, Kota et al.
115 injected mice with AAV.miR-26a in the
context of hepatic cancer. The rise in miR-26a resulted in protection
from cancer progression without signs of toxicity. Delivery of these
agents to speciﬁc tissue targets poses a further problem. Different
AAV serotypes have been shown to favour speciﬁc tissues, for
example serotypes 6, 8, and 9 are predominantly directed to skeletal
muscle, liver, and the heart, respectively.
116 These results suggest the
promises of AAV-mediated miRNA therapeutics. We have also
successfully used an adenoviral vector to convey a decoy to inhibit
miR-503, which is pathogenic in the setting of diabetic limb ischae-
mia.
74 However, for their short transgene expression, adenovirus
may not be the best approach to treat diabetes and its chronic
complications in the clinical arena. Another therapeutic strategy
involves ‘miRNA sponges’. These artiﬁcial miRNA decoys bind
native miRNA to create a loss of function of a particular miRNA.
These sponges contain multiple binding sites directed against a
particular miRNA or against an miRNA seed sequence family.
117
miRNA sponges have already been used in vivo to decrease the activity
of miR-31 and its role in cancer development.
118 The use of miRNA
sponges in an AAV vector delivery system maybe a potential
novel strategy for miRNA therapeutics. While the ﬁrst reports on
miRNA therapeutics are encouraging, the fact that a typical miRNA
targets several genes suggests that clinical intervention may be very
complex.
9. Conclusions
miRNAs belong to a class of non-coding RNAs which are involved in
the pathogenesis of several diseases. Although many miRNAs have
already been identiﬁed, their predicted target genes need to be fully
researched and functionally characterized. The complexities in the
pathogenesis of diabetes make this more challenging. Emerging evi-
dence suggests that miRNAs are differentially expressed, and indeed
have a potential causative role, in diabetes and its related cardiovascu-
lar complications. In future, these mechanisms may be exploited to
help deﬁne speciﬁc clinical biomarkers and allow appropriate thera-
peutic intervention in the management of diabetes.
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